The inclusion criteria were male sex, no history of dapoxetine treatment, age older than 19 years, and involvement in a stable monogamous relationship with a female sexual partner. The mean age of all patients was After 12 months, the discontinuation rate decreased sharply Figure 1. The economic costs of dapoxetine should be assessed individually in all the countries where it is approved, since the relative costs to the health care provider differ according to local health care structure, currency, and costs of alternative therapy. Importantly, the partners of subjects in these trials also reported significant improvements in satisfaction with sexual intercourse at every time point, suggesting possible associated reductions in interpersonal difficulty not measured in these studies. · Although dapoxetine is the only oral pharmacologic agent approved for the treatment of premature ejaculation (PE) and is very effective, the discontinuation rate is . Dapoxetine is not approved for marketing in the United States. Dapoxetine is a drug specifically developed for the on-demand treatment of PE and is the first oral . This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon .